Daptomycin intravenous - Mylan/Phosphagenics

Drug Profile

Daptomycin intravenous - Mylan/Phosphagenics

Alternative Names: TPM® Daptomycin

Latest Information Update: 10 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Phosphagenics
  • Developer Mylan; Phosphagenics
  • Class Antibacterials; Cyclic peptides; Lipopeptides; Peptide antibiotics; Small molecules
  • Mechanism of Action Cell membrane inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Bacteraemia; Skin and soft tissue infections

Most Recent Events

  • 07 Mar 2017 Chemical structure information added
  • 01 Nov 2015 Late-stage clinical development in Bacteraemia in USA (IV)
  • 01 Nov 2015 Late-stage clinical development in Skin and soft tissue infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top